Page last updated: 2024-12-08
salicylacyl glucuronide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
salicylacyl glucuronide: structure given in first source; RN given refers to (beta-D)-isomer; RN for cpd without isomeric designation not available 11/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 168876 |
| MeSH ID | M0181439 |
Synonyms (15)
| Synonym |
|---|
| 29315-53-5 |
| salicylacyl glucuronide |
| (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(2-hydroxybenzoyl)oxyoxane-2-carboxylic acid |
| acyl sa glucuronide |
| salicyl acyl glucuronide |
| beta-d-glucopyranuronic acid, 1-(2-hydroxybenzoate) |
| (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[(2-hydroxyphenyl)carbonyloxy]oxane-2-carboxylic acid |
| salicylic acid acyl-beta-d-glucuronide |
| 1-(2-hydroxybenzoate |
| 1-(2-hydroxybenzoic acid |
| 1-(2-hydroxybenzoate) beta-d-glucopyranuronic acid |
| 1-(2-hydroxybenzoate) beta-delta-glucopyranuronic acid |
| 1-o-(2-hydroxybenzoyl)hexopyranuronic acid |
| DTXSID70951878 |
| salicylic acid, beta-d-glucopyranuronosyl ester |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Pathways (1)
| Pathway | Proteins | Compounds |
|---|---|---|
| Trehalose Degradation I (Low Osmolarity) | 5 | 9 |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||